Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Confirmed with this link
https://fintel.io/ss/us/amc
Trading as if some negative news is coming
Now 5.51%.....Slowly climbing
It’s out now -up to 5.28%
And just like that....now reporting 400k shares
shady
It’s over - $8 war is lost
Big boys always win....sad sad
Add to top of page????
Game Over I think
Love the analogy
Bio - hope you are right. I think the battle is lost at $8......I think they push it under that number by COB unfortunately.
Many are right behind you.....best of luck!!!
It’s almost like they want the notoriety of trying a case in front of the SC instead of just doing the Rule 60?
RIDICULOUS
Look at louieblouie posts
This was filed late last night - anyone have access to PACER to read updated claim?
REPLY BRIEF re19 MOTION to Dismiss for Failure to State a Claim Hikma's Reply Brief in Support of Motion to Dismiss First Amended Complaint filed by Hikma Pharmaceuticals PLC., Hikma Pharmaceuticals USA Inc.. (Gattuso, Dominick)
Hey Bio - did you give up on AMRN
Thank you kind sir
China question
I know that Amarin gets certain milestone payments from their partner in China. I thought one of the milestones was around regulatory acceptance of application, but I can’t find anything to confirm that. Thoughts?
If anything material is presented today on COVID at 4 ...Amarin will have to issue PR prior to results being shared I would guess?
YES - something like this must be done.
Earnings call happening now
Was the NASH trial with VASCEPA one of the trials that Gilead stated today they put on hold because of COVID?
SAVA experiencing what AMRN will soon
Dr.Reddy getting ready for launch? This taken from call notes;
Erez Israeli
Yes. So the -- we had the triggering event of the launch of Nobel and Vascepa and the -- and we have worked in accordance to the good accounting practices, as we see the attributed base events for that. We are still planning to launch these products and I don’t -- there is no plans to reverse that, I hope and believe that we will launch these products and make money from them.
Many thanks for that info
He is one of the top execs
STEVEN KETCHUM, PHD
SVP, PRESIDENT OF R&D AND CHIEF SCIENTIFIC OFFICER
He could have had some sell parameters set in his account that triggered the sell once we touched $8 - that is quite plausible.
If he did not - then this is a scream “Heck No” there is no buy out action.
Something smells wrong
For the 1,000,000th time with AMRN
About to go RED - AWESOME
Maybe label will be restrictive? - volume and price action does not add up?
MEETING was suppose to end at 3....meeting is over
It’s not +6 hours ?
It’s late in the afternoon in Europe!!!!
<twiddling thumbs emoji>
Great job Amarin - great price action on the eve of incredible news
Or release it on the weekend ....so sad
HUGE news probably to drop tomm.....and we are down....nothing makes sense anymore in this market.
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
NEWS PROVIDED BY
HLS Therapeutics Inc.
Jan 28, 2021, 06:30 ET
Vascepa included in Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology1
Chinese Society of Cardiology updated Guidelines now include Vascepa in its Prevention of Cardiovascular Diseases
Vascepa is now included in the treatment guidelines or otherwise recommended for use by 13 medical associations worldwide including Thrombosis Canada2-14
HLS expects the Canadian Cardiovascular Society will review and potentially update its lipid management guidelines in 2021
TORONTO, Jan. 28, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces new support from independent medical societies for the use of Vascepa (icosapent ethyl) in reducing the risk of a Major Adverse Cardiovascular Event (MACE).
In the recent Consensus Statement by the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm 2020 executive summary1, the AACE treatment algorithm recommends that Vascepa should be added to a statin for any patient with established atherosclerotic cardiovascular disease (ASCVD) or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent cardiac events. In addition, on January 21, 2021, it was announced that the Chinese Society of Cardiology had included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include "icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT®) as a treatment consideration to further lower ASCVD in the appropriate patient population."15
Vascepa (icosapent ethyl) is now included in the treatment guidelines or otherwise recommended for use by 13 medical associations worldwide.2-14 These include American Diabetes Association; American Heart Association; National Lipid Association; American Association of Clinical Endocrinologists; American College of Endocrinology; Endocrine Society; European Society of Cardiology; European Atherosclerosis Society; Chinese Society of Cardiology; Japan Circulation Society; Brazilian Society of Cardiology; and Thrombosis Canada. HLS expects that the relevant guidelines from the Canadian Cardiovascular Society will be reviewed and may be updated in 2021.
"Cardiovascular disease remains the number one killer worldwide1 and the inclusion of Vascepa in treatment guidelines from leading medical associations across the globe further validates the acceptance of this unique drug to reduce the risk of a MACE in cardiac or diabetic patients," said Gilbert Godin, CEO of HLS. "Vascepa is a first-in-its-class medication and with substantial clinical evidence behind it, we believe that there is an urgent and genuine need for the product in the Canadian market today."
I’m on the conference call this morning listening to their launch plans and it’s almost comical how much better, professional, and just more organized the mgmt team is as compared to our AMR team.